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ReceptorHuman respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infection in
infants, immunocompromised patients, and the elderly. The RSV fusion (F) protein mediates fusion of the
viral envelope with the target cell membrane during virus entry and is a primary target for antiviral drug and
vaccine development. The F protein contains two heptad repeat regions, HR1 and HR2. Peptides
corresponding to these regions form a six-helix bundle structure that is thought to play a critical role in
membrane fusion. However, characterization of six-helix bundle formation in native RSV F protein has been
hindered by the fact that a trigger for F protein conformational change has yet to be identiﬁed. Here we
demonstrate that RSV F protein on the surface of infected cells undergoes a conformational change following
exposure to elevated temperature, resulting in the formation of the six-helix bundle structure. We ﬁrst
generated and characterized six-helix bundle-speciﬁc antibodies raised against recombinant peptides
modeling the RSV F protein six-helix bundle structure. We then used these antibodies as probes to monitor
RSV F protein six-helix bundle formation in response to a diverse array of potential triggers of
conformational changes. We found that exposure of ‘membrane-anchored’ RSV F protein to elevated
temperature (45–55 °C) was sufﬁcient to trigger six-helix bundle formation. Antibody binding to the six-
helix bundle conformation was detected by both ﬂow cytometry and cell-surface immunoprecipitation of the
RSV F protein. None of the other treatments, including interaction with a number of potential receptors,
resulted in signiﬁcant binding by six-helix bundle-speciﬁc antibodies. We conclude that native, untriggered
RSV F protein exists in a metastable state that can be converted in vitro to the more stable, fusogenic six-
helix bundle conformation by an increase in thermal energy. These ﬁndings help to better deﬁne the
mechanism of RSV F-mediated membrane fusion and have important implications for the identiﬁcation of
therapeutic strategies and vaccines targeting RSV F protein conformational changes.
Published by Elsevier Inc.Introduction
Human respiratory syncytial virus (RSV) is an enveloped negative-
sense ssRNA virus of the pneumovirus group in the paramyxoviridae
family (Collins et al., 2001). RSV is a major cause of pediatric
respiratory disease, resulting in severe lower respiratory tract
infection in infants, immunocompromised patients, and the elderly
(Collins et al., 2001). There are no effective vaccines available for RSV.
Currently approved antiviral therapy for RSV infection is limited to
ribavirin, a broad-spectrum antiviral drug with limited efﬁcacy.edel).
e Orchard Road, Gaithersburg,
ute of Allergy and Infectious
MD 20892, USA. Fax: +1 301
Inc.Prophylactic treatment with the anti-RSV monoclonal antibody,
palivizumab, is effective in reducing the severity of disease but is
only recommended for high-risk patients (Johnson et al., 1997;
Groothuis et al., 1993; Pollack and Groothius, 2002). Therefore,
development of new therapies for the treatment of RSV infection is a
high priority.
RSV enters cells by binding to the target cell surface and fusing its
envelopewith the plasmamembrane of the target cell. There are three
viral glycoproteins on the envelope surface: the attachment glyco-
protein (G), the fusion (F) protein, and the small hydrophobic (SH)
protein (Heminway et al., 1994). However, several lines of evidence
indicate that only F, the fusion protein, is both necessary and sufﬁcient
for virus entry and cell fusion (Karron et al., 1997; Kahn et al., 1999;
Teecharpornkul et al., 2001). Thus, the critical role of the F protein
in virus entry, along with the fact that F is highly conserved and is a
major antigen for neutralizing antibodies, makes it an attractive
therapeutic target (Johnson et al., 1987; Eckert et al., 1999; Collins
et al., 2001; Zhao et al., 2000).
227A.S. Yunus et al. / Virology 396 (2010) 226–237The RSV F protein is synthesized as a 70-kDa precursor (F0) that is
processed by proteolytic cleavage in the trans-Golgi complex to yield
two disulphide-linked subunits: F1 and F2 (Fig. 1A; Anderson et al.,
1992; Collins and Mottet, 1991; Collins et al., 1984). The mature F
protein is expressed as a homotrimer on the cell surface (Calder et al.,
2000). The ectodomain of the F1 transmembrane subunit contains
two heptad repeat regions, HR1 and HR2, and an N-terminal fusion
peptide (Fig. 1A) (Collins et al., 2001). Processing of the F0 precursor
has been proposed to generate a “metastable” F1/F2 complex (Zhao
et al., 2000). In one proposed model, receptor binding triggers
conformational changes in the metastable F protein, resulting inFig. 1. Construction of RSV fusion (F) protein heptad repeat peptide immunogens. (A) Hep
domains of the F1 subunit are shown, including the heptad repeats, HR1 (or N region) and HR
subunit, the location of an additional predicted heptad repeat, HR3, is shown. Cleavage sites
The location of conserved glycosylation sites are denoted by lollipop-shaped structures in
construct. The nucleotide sequence of the codon-optimized HR1/HR2 cDNA is shown. Th
expression in E. coli are italicized. The HR1 region (nt 13–187, encoding F residues 153–209)
(underlined sequence). Also shown are the locations of restriction enzyme cloning sites and
sequences identical to the corresponding regions shown here. The cDNAs expressing RSV p
expression plasmid. (C) Sequence of recombinant RSV peptides (N, C, or single chain NC pepti
are shown.insertion of the N-terminal fusion peptide into the target cell
membrane. The HR1 and HR2 heptad repeat regions then interact to
form a six-helix bundle structure (Carr et al., 1997; Eckert and Kim,
2001). According to this model, formation of the six-helix bundle
structure facilitates membrane fusion by bringing the viral and
cellularmembranes into close apposition (Chan and Kim, 1998; Eckert
and Kim, 2001; Russell et al., 2001). The presence of heptad repeat
regions that are capable of associating to form a six-helix bundle
structure is a feature of several enveloped virus fusion proteins,
suggesting a common membrane fusion mechanism (Lamb, 1993;
Hernandez et al., 1996; Melikyan et al., 2000; Skehel andWiley, 2000;tad repeat (HR) domains and other structural features in the RSV fusion protein. Key
2 (or C region), the fusion peptide (FP), and the transmembrane domain (TM). In the F2
designate the location of furin cleavage sites in F2 and the F2–F1 junction, respectively.
F2 and F1. (B) Codon optimization of HR1/HR2 cDNA in an RSV peptide expression
e wild-type RSV A2 strain F gene nucleotides that were replaced to permit optimal
and HR2 region (nt 232–366, encoding F residues 476–520) are joined by a linker region
the IEGR- factor-Xa cleavage sequence. The individual HR1 and HR2 cDNA clones have
eptides NC, N, or C were cloned into the BamHI-HindIII window of the pET-32a protein
de) generated in the study. The lengths and predictedmolecular weights of the peptides
228 A.S. Yunus et al. / Virology 396 (2010) 226–237Lamb and Kolakofsky, 2001). In support of this model, peptides
corresponding to the RSV F protein HR1 and HR2 regions (N and C
peptides, respectively) have been shown to form a six-helix coiled–
coil bundle structure, wherein three C peptides pack in an antiparallel
fashion into the outer grooves of a central N peptide trimeric coiled–
coil (Fig. 3B) (Zhao et al., 2000; Matthews et al., 2000; Lawless-
Delmedico et al., 2000). This model is also supported in part by the
fact that C peptides are often potent inhibitors of fusion mediated by
viral fusion proteins, including the RSV F protein (Lambert et al., 1996;
Wang et al., 2003). In the case of HIV, C peptide inhibitors have been
shown to interact with the HR1 region of the HIV gp41 fusion protein
during an intermediate stage of conformational change to form a
dead-end peptide-gp41 hybrid six-helix bundle structure (Kilgore
et al., 2003). One HIV C peptide inhibitor, enfuvirtide, has been
approved for the treatment of HIV infection. Thus, inhibition of viral
fusion protein six-helix bundle formation is a validated therapeutic
approach for the treatment of viral disease (Wild et al., 1992, 1994;
Chan and Kim, 1998; Eckert et al., 1999; Zhao et al., 2000).
The description of a six-helix bundle structure formed by N and C
peptides derived from RSV F protein, along with the fact that RSV C
peptides potently inhibit fusion, suggests that RSV F protein under-
goes conformation changes during fusion that are analogous to those
described in the HIV, SV5, inﬂuenza, and related viral systems.
Electron microscopy studies of RSV F protein have revealed that
trypsin treatment causes a change in conformation from a lollipop-
shaped structure to a cone-shaped structure, which are thought to
represent the native and fusion-active states, respectively (Calder
et al., 2000). However, it has yet to be demonstrated directly that
native, membrane-anchored RSV F protein can be triggered to
undergo conformational changes leading to the formation of a six-
helix bundle structure. Indeed, it is not yet known what triggers these
conformational changes. Since, like HIV, RSV fusion takes place at the
cell surface and is pH-independent (Srinivasakumar et al., 1991; Collins
et al., 2001), it is presumed thatbindingof F protein to a cellular receptor
triggers conformational changes. Although several ligands have been
identiﬁed that bind toRSVFprotein, it remains unclearwhether any one
of these ligands is a bona ﬁde receptor for RSV (Pastey et al., 2000;
Behera et al., 2001; Sano et al., 2003; Hallak et al., 2000). The lack of a
system in which to study native RSV F protein six-helix bundle
formation hinders the development of therapeutics targeting F protein
conformational changes.
In the present study, we generated conformation-speciﬁc anti-
bodies to recombinant peptide immunogens modeling the RSV F
protein six-helix bundle structure. We show that a low level of RSV F
protein in the six-helix bundle conformation exists on the surface of
RSV-infected cells in a culture that is actively undergoing fusion. We
utilized the six-helix bundle-speciﬁc antibodies as probes to charac-
terize potential triggers of F protein conformational change. We
determined that elevated temperature serves as an efﬁcient in vitro
trigger of F protein conformation change leading to six-helix bundle
formation. The implications of these ﬁndings for the development of
antiviral therapeutics or vaccines targeting the RSV F protein are
discussed.
Results
Expression of immunogens modeling the RSV F protein six-helix bundle
In order to generate antibodies against RSV 6HB, peptides corre-
sponding to the HR regions of RSV F protein were expressed to
generate immunogens thatmimic the RSV-F fusion core 6HB structure.
We ﬁrst engineered codon-optimized synthetic bacterial expres-
sion constructs expressing a linked N and C single-chain peptide (NC),
the N peptide, or the C peptide using sequences derived from thework
of Zhao et al. (2000) (Fig. 1). In each synthetic cDNA construct,
selected nucleotide residues in the HR1 and HR2 coding sequencesfrom wild-type RSV F cDNA (accession no. VGNZA2) were replaced
with residues that favor optimal expression in Escherichia coli
(Fig. 1B). The recombinant RSV peptides (N, C, and NC single-chain)
were expressed as histidine (His)-tagged fusion peptides in E. coli
(Fig. 1B). The His-tag was cleaved off with factor-Xa, the peptides
were desalted, lyophilized, and resuspended at a concentration of
∼0.5 mg/ml in water.
The linked single-chain NC peptide or a 1:1mixture of individual N
and C peptides (N+C) are hypothesized to form a complex in vitro
that mimics the authentic 6HB structure formed due to coiled–coil
interactions of RSV-F HR α-helical domains during the fusion process.
The 14-amino-acid-long glycine-rich peptide inserted between the N
and C domains allows for folding and interaction between the arms of
the NC peptide (Fig. 1C).
Characterization of recombinant RSV peptides
The recombinant RSV peptides were analyzed by SDS-PAGE
before and after factor-Xa cleavage to determine their approximate
molecular weights. The larger size of the His-tagged peptides is due
to the presence of uncleaved TRX, Thrombin, and S-Tags encoded in
the pET-32a leader sequence that precedes the engineered IEGR
(factor-Xa ) RSV peptides (N, C, and NC) (Fig. 1C). Factor-Xa
enzyme-mediated cleavage of the His-tagged peptides releases free
N, C, or NC peptide, respectively (Fig. 1C). The predicted molecular
weights of the N (57 aa), C (45 aa), and NC (116 aa) peptides based
on their amino acid (aa) sequences were 6.13, 5.11, and 12.21 kDa,
respectively (Fig. 1C). The migration pattern of the RSV peptides
relative to a 36-amino-acid (4.5 kDa) control peptide (DP-178) and
molecular weight markers coincided well with their predicted
molecular weights (compare Fig. 2A with Fig. 1C).
To determine whether antibodies to RSV could recognize the
recombinant peptides, an immunoblot of the recombinant peptides
was probed using RSV neutralizing polyclonal serum. The αRSV
polyclonal serum recognized the N and NC peptides, thus conﬁrming
that these peptides contained authentic F protein epitopes (Fig. 2B).
Surprisingly, the C peptide did not appear to react with αRSV serum;
only faint background bands were seen, likely attributed to cross-
reactivity with contaminating bacterial proteins. One possible expla-
nation for this observation is the presence of a conserved N-linked
glycosylation site (aa: 500NQS502) within the HR2 (C peptide region)
domain in the fusion protein (Figs. 1A and C, Collins et al., 2001;
Zimmer et al., 2001). Perhaps the presence of the carbohydrate side
chain makes this region poorly antigenic. Alternatively, the HR2-C
region may be buried within the native, untriggered RSV F protein
oligomer and inaccessible to circulating antibodies. Studies of soluble
F proteins suggest that this latter explanation is unlikely, since the
HR2 region is proposed to form a stalk structure in the pre-fusion state
(Lamb and Jardetzky, 2007).
Antiviral activity of RSV peptides
The C (HR2) and N (HR1) peptides have been reported to potently
inhibit RSV fusion and infection (Lambert et al., 1994; Wang et al.,
2003). To determine whether the peptides that we generated had
antiviral activity, we tested each peptide (N, C, NC, or an N+C
mixture) for its ability to inhibit RSV infection and syncytia formation
in vitro in a dose–response assay. Consistent with previous observa-
tions (Lambert et al., 1996; Wang et al., 2003), both the N and C
peptides were found to inhibit RSV infection (data not shown). Also
consistent with previous reports, the C peptide was found to be more
potent than the N peptide (IC50=8.0 μg/ml [1.6 μM] and 62.5 μg/ml
[10.2 μM], respectively). The existence of a prehairpin intermediate
conformation for RSV F1 is strongly supported by our observation and
by others that RSV infection can be potently inhibited by HR-C
peptides (Lambert et al., 1996; Wang et al., 2003).
Fig. 2. Characterization of the recombinant RSV HR peptides. (A) Coomasie stained
polyacrylamide gel showing the molecular weights of the histidine-tagged fusion
peptide and puriﬁed RSV peptides (N, C, or NC) released by factor-Xa cleavage of the
corresponding histidine-tagged fusion proteins. A commercially synthesized HIV
peptide, DP-178 (∼4.5 kDa in size), was included for comparison. (B) αRSV serum
recognizes the peptides, N and NC but not the C peptide in an immunoblot. The arrow
indicates the predicted migration for the C peptide that was not recognized by αRSV
serum. (C) Circular dichroism spectra of the NC single-chain peptide are consistent
with a 6HB solution structure. The double minima at 222 and 208 nm are characteristic
of the high level of helical secondary structure found in a 6HB.
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noticeable antiviral activity (data not shown). Similarly, mixing N and
C peptides together in equimolar ratio (N+C) resulted in the loss ofantiviral activity of either peptide, presumably due to 6HB-like
structure formation (data not shown).
Circular dichroism reveals that the RSV peptide NC or an equimolar
mixture of N and C peptides (N+C) assumes a helicity characteristic
of a six-helix bundle structure
Circular dichroism (CD) was performed to determine whether the
peptides NC or N+C have the solution structures similar to those
predicted for the RSV fusion core from previous studies (Matthews et
al., 2000; Lawless-Delmedico et al., 2000; Zhao et al., 2000). The
formation of the 6HB structure is marked by a signature increase in
helicity that can be detected by CD spectroscopy upon mixing of
individual N and C peptides (Zhao et al., 2000; Matthews et al., 2000;
Lawless-Delmedico et al., 2000; Wild et al., 1992). We therefore
analyzed the helicity of the NC peptide (or a 1:1 mixture of N and C
[N+C]). The CD spectra for a 10 μMsample of peptideNC in PBS at 4 °C
displayed a double minima at 222 and 208 nm that is characteristic of
the high degree of α-helical secondary structure found in the 6HB
complex (Fig. 2C). The mean molar elipticity value of −27,000 at
222 nm indicates that under the conditions of the experiment,
the protein is ∼85% helical. Similar results were obtained with a 1:1
mixture of the individual N and C peptide constructs (data not
shown). These data indicate that the complex formed by the
recombinant RSV peptides, NC or N+C, models the 6HB structure
in a manner similar to peptides utilized in previous studies (Lawless-
Delmedico et al., 2000; Matthews et al., 2000; Zhao et al., 2000).
Peptide ELISA demonstrates that the antibodies generated against
recombinant peptide complexes are speciﬁc for 6HB epitopes
Having established that these peptides possess the characteristics of
a 6HB structure, the recombinant peptide complexes NC or N+Cwere
used as immunogens to raise antibodies that would recognize the 6HB
epitope generated during the RSV F-mediated fusion process. Three
guinea pigs were immunized with each immunogen (NC or N+C
mixed peptides). We have used this approach previously to generate
antibodies against the HIV gp41 6HB structure that forms following
triggering with CD4 (de Rosny et al., 2001; Furuta et al., 1998).
A peptide-based indirect ELISAwas used for initial characterization
of the antiserum. The peptides NC or N+C were highly immunogenic
and yielded relatively high-titer antiserum (Fig. 3A), which we
designated asα-NC orα-N+C. The antibody responses were directed
primarily against peptide complexes NC or N+C rather than
individual peptides N or C (Fig. 3B). Furthermore, the reactivity of
antiserum α-NC (or α-N+C) to peptides NC or N+C could be
completely adsorbed out by either immunogens (NC or N+C) but not
by free peptides N or C (Fig. 3C). These observations demonstrate that
α-NC antibodies predominantly recognize 6HB-speciﬁc epitopes. The
αNC or α-N+C antiserum did not react with a peptide complex
corresponding to HIV 6HB (P15+P16) indicating its speciﬁcity to RSV
6HB (data not shown). Our results are also supported byﬁndings in the
HIV system, wherein a polyclonal 6HB-speciﬁc antiserum displayed
similar speciﬁcity to a gp41 6HB peptide complex (de Rosny et al.,
2001). Collectively, these results demonstrate that the antiserum
generated against the NC or N+C peptides was predominantly
complex-speciﬁc and therefore suitable to probe for RSV-F 6HB
structure. Since the αNC antibodies displayed a higher titer (Fig. 3A)
as well as lower cross-reactivity to free peptides N or C (Fig. 3B), this
antiserum (84F=αNC; Fig. 3A) was used for further characterization.
αNC recognizes RSV F protein in lysate strips as well as
lysate immunoprecipitation
The antiserum αNC (or αN+C), when used to probe lysate strips
prepared from RSV-infected cells, reacted to protein with molecular
Fig. 4.αNC antiserum recognizes epitopes located in the F1 subunit. (A)αNC antiserum
recognizes RSV F protein in RSV lysate Western blot strips. The reactivity of αRSV
serum is shown as a control. (B) αNC antiserum selectively immunoprecipitates F1
subunit from RSV-infected cell lysate. Pre-immunization serum (PI) from guinea pig
#84 is run as a negative control. RSV proteins immunoprecipitated by two RSV αF
monoclonal antibodies (858-1-Sigma and 3216-Serotec) and polyclonal αRSV serum
were run as controls.
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(F0) protein (Fig. 4A), suggesting that these antisera recognized
epitopes in the RSV F protein.
In immunoprecipitation (IP) experiments, the αNC (or αN+C)
antiserum immunoprecipitated F1 subunit from RSV-infected cell
lysate, but no F0 form whatsoever was observed (Fig. 4B). These
results are consistent with theαNC antibody epitopes being located in
the F1 subunit (Fig. 4). The lack of binding to F0 was interesting, since
studies of soluble hPIV3 F protein suggest that cleavage of the F
precursor is not required for adoption of a post-fusion conformation
(Lamb and Jardetzky, 2007). It may be that the requirements for 6HB
formation differ between soluble and native, membrane-bound F
proteins (Ruiz-Arguello et al., 2004; Yin et al., 2005, 2006).
Conversely, the reactivity of the αNC antibody to the F0 form of RSV
F protein in the Western blot (Fig. 4A) could either be non-speciﬁc or
result from small amounts of antibodies against uncomplexed N and CFig. 3. Assessment of immune response against the immunogen using a peptide ELISA.
(A) ELISA titers demonstrate the immunogenicity of peptide antigen NC or N+C.
Antibody response of individual guinea pigs immunized with immunogen NC (guinea
pig #82, #83, and #84) or N+C (guinea pig #85, #86, and #87) indicated that antisera
#84 (NC) and #87 (N+C) displayed the highest titers. (B) Antisera αNC (#84) and
αN+C (#87) are qualitatively identical in that they display the highest reactivity to
peptide complexes, NC or N+C, rather than to either of the free peptides N or C. The
αNC antiserum displayed the lowest cross-reactivity to the individual N or C free
peptides. Data are representative of two experiments. The dilution of αNC antibody
used was 1:10,000. (C) Peptide adsorption ELISA demonstrates the speciﬁcity of αNC
antiserum to RSV 6HB epitope. Adsorption of αNC antiserum with peptide complex NC
or N+C abolishes the reactivity to NC (6HB) peptide. Adsorption with individual free
peptide N or C does not signiﬁcantly affect the reactivity to NC (6HB) peptide. The
dilution of αNC antibody used was 1:10,000.
Fig. 5. Immunoprecipitation of F protein from the surface of RSV-infected cells using
αNC antibodies. Cell-surface IP demonstrates the presence of 6HB epitopes on the
surface of RSV-infected cells actively undergoing fusion. Cell-surface reactivity to these
epitopes can be adsorbed outwith NC or N+C peptidemixtures but not with individual
N or C peptides.
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Collectively, the above ﬁndings, along with the results of the peptide
ELISA, strongly suggest that the F1 epitope recognized by the αNC
antiserum is the RSV 6HB structure (Fig. 3 and 4).
Cell-surface IP adsorption experiment demonstrates the speciﬁcity of
antibodies for the RSV F six-helix bundle
We next employed cell-surface immunoprecipitation to determine
if 6HB epitopes could be found on the surface of RSV-infected cells
that are actively undergoing cell fusion. Using the αNC serum, F1
subunit was immunoprecipitated from the surface of RSV-infected
cells (Fig. 5B). In order to determine if the F1 being immunopre-
cipitated from the cell surface was indeed a 6HB conformation of F1,
we adsorbed the αNC antiserum with peptides N, C, NC, or N+C,
respectively, and used this serum in cell-surface IP experiments. Our
results show that adsorption of the antiserumwith NC (or N+C; data
not shown) peptides that mimic the RSV F 6HB structure completely
abolished the capacity of αNC antiserum to immunoprecipitate F1
protein. Whereas adsorption with peptides N or C alone did not
prevent F1 binding (Fig. 5B).
The peptide adsorption cell-surface IP results, along with pep-
tide ELISA binding data, demonstrate that α-NC antibodies are
conformation-speciﬁc for 6HB epitopes and, therefore, can be used to
detect the ﬁnal conformation state of the RSV F protein. Our results
provide proof-of-concept that, starting with synthetic peptide immu-
nogens that mimic the RSV F 6HB structure, it is possible to generate
antibodies that speciﬁcally bind the 6HB epitopes being created on the
surface of RSV-infected cells undergoing fusion.Fig. 6. Detection of F protein 6HB epitopes on the surface of RSV-infected cells. Flow cytome
protein is recognized by anti-6HB (αNC) antiserum on the surface of RSV-infected cells. (B) B
α-F monoclonal antibody.Search for a method to trigger six-helix bundle formation
Using ﬂow cytometry, the staining of RSV-infected cells with αNC
antiserum detected the presence of a low level of F protein in the 6HB
conformation on the cell surface (Fig. 6A). The mean ﬂuorescence due
to antibody binding to 6HB epitopes was signiﬁcantly lower in
comparisonwith the total F protein detected using anα-F monoclonal
antibody (Fig. 6B). These data generated using ﬂow cytometry
correlated well with cell-surface IP results and suggested that a low
level of F protein 6HB exists on the surface of RSV-infected cells.
Using ﬂow cytometry, we rapidly ruled out the possibility that the
following conditions/reagents would trigger a conformation change
in cell-surface expressed RSV F into its fusion active six-helix bundle
formation: (1) addition of reported F-interacting proteins such as
RhoA or ICAM-1 or glycosaminoglycans (such as heparin, heparan
sulphate, dextran sulphate, or chondroitin B); (2) human or bovine
lactoferrin, reported to interact with G or F glycoprotein; (3) exposure
to different pH (3.2–11.0) or trypsin or disulphide bond reducing
agents (β-Mercaptoethanol or dTT) or denaturing agent (SDS) (data
not shown).
Temperature as an efﬁcient trigger of RSV F protein six-helix
bundle formation
Previous work using a soluble form of the F protein from para-
inﬂuenza virus type 5 (PIV5) demonstrated an effect of temperature
on the conformational state of the protein (Connolly et al., 2006). To
determine if elevated temperature could trigger 6HB formation in
native RSV F protein, we incubated RSV-infected cells for 5 min at 4 or
37 °C or a range of temperature from 37 to 65 °C prior to staining with
6HB antibody. Following incubation at temperatures between 45 and
55 °C, a speciﬁc increase in staining of RSV-infected cells, but not
uninfected control cells, was observed (Fig. 7A and data not shown).
Repeated testing of the effects of temperature on triggering during a
5-min incubationusing a thermocycler revealed that triggering reaches
a plateau between 50 and 55 °C (Fig. 7A). At 55 °C, the level of staining
by 6HB-speciﬁc antibody was almost equivalent to that observed with
an anti-F monoclonal antibody-positive control (data not shown),
suggesting that a large proportion of the total population of F protein
expressed on the cell surface was triggered under these conditions.
In order to identify the optimal time for triggering RSV-infected
Vero cells were incubated at 55 °C for various lengths of time up to an
hour prior to staining. Exposure to 55 °C for a 15-min duration
resulted in the most dramatic/rapid increase in triggering (Fig. 7B).try of αNC antibody-stained intact cells demonstrates: (A) a relatively low amount of F
y comparison, a large amount of total F protein is detected on RSV-infected cells using an
Fig. 7. Identiﬁcation of temperature as a trigger of 6HB formational change in a ﬂow
cytometry-based triggering assay. (A) Temperature course ( 5-min incubation) at 37,
40, 42.5, 45, 47.5, 50, 52.5, 55, 57.5, and 60 °C. Temperature-dependent triggering starts
around 42.5 °C and plateaus between 47.5 and 55 °C, where a maximum signal to noise
ratio of 2.4–2.5 times that observed at 37 °C (1.4) is achieved. (B) Time course at 55 °C
for 5 , 15 , 30 , 45 , and 60 min. 6HB formation occurs rapidly within the ﬁrst 5 min of
exposure to 55 °C. (C) Loss of staining of α-NC antiserum upon adsorption with a
mixture of N+C peptides but not with N or C peptide alone. Triggering was performed
for 15 min at 55 °C.
232 A.S. Yunus et al. / Virology 396 (2010) 226–237Only small and gradual increases in triggering were observed beyond
15-min exposure up to 45 min, and then this effect subsided. These
data, along with the results of 5-min temperature course experi-
ments (Fig. 7A), demonstrated that a short incubation of 5–15 min at
50–55 °C was sufﬁcient to trigger optimal 6HB formation on the
surface of RSV-infected cells.
Triggering was compared for four different cell lines: Vero, Hep2,
HeLa, and Hela-S3. The results demonstrated that the best combina-
tion of F expression and triggering signal to noise was observed with
Vero cells (data not shown).
In order to conﬁrm that the 55 °C incubation was not having
deleterious effects on cell membranes, RSV-infected Vero cells treated
at 55 °C for 0.5 h were stained with antibodies that recognize two
intracellular constituents: (1) Rho A (found on the intracellular face of
the plasmamembrane) or (2) the Golgi complex (Sigma Golgi-speciﬁc
antibody #2404). We observed that ﬂow cytometry staining to RhoA
or the Golgi complex was dramatically increased in uninfected Vero
cells following treatment with detergent-containing buffer (Perm 2,
BD Biosciences); whereas no increase was observed following
incubation at 55 °C for 0.5 h in the absence of detergent (data not
shown). These results demonstrated that signiﬁcant cell permeabili-
zation was not occurring at 55 °C, and the triggering detected at that
temperature was, instead, due to 6HB formation in cell-surface
expressed F protein. The speciﬁcity of the staining following a 55 °C
trigger was further conﬁrmed in experiments, which showed that no
signiﬁcant staining above background was observed following
adsorption of antibodies to 6HB complexes in an N+C peptide
mixture (Fig. 7C).
Cell-surface IP demonstrates a temperature-dependent increase
in triggering
A cell-surface immunoprecipitation experiment was performed in
which 6HB-speciﬁc αNC antiserum was incubated with RSV-infected
cells at increasing temperatures for 15 min. Following this triggering
step, unbound antibody was washed away, and the immune
complexes were then immunoprecipitated. As is shown in Fig. 8A,
the amount of RSV F protein on the cell surface that was recognized by
αNC antiserum was signiﬁcantly increased at temperatures above
37 °C, with the highest level being pulled down at 50–55 °C. These
results were consistent with the results presented in Fig. 7 from ﬂow
cytometry experiments and conﬁrmed that the increased antibody
binding detected at elevated temperature was speciﬁc for the RSV F
protein.
To conﬁrm the speciﬁcity of the antibody binding to the six-helix
bundle conformation of RSV F following temperature triggering, a
cell-surface IP experiment was performed in which 6HB-speciﬁc NC
antiserum was pre-incubated with either the N, C, or NC single-chain
peptide or a mixture of the N and C peptides (N+C) prior to
incubation with RSV-infected cells at 55° C for 15 min. As is shown in
Fig. 8B, virtually all of the reactivity of the NC antiserum for
temperature-triggered RSV F protein was adsorbed out by the NC
single-chain 6HB peptide or an equimolar mixture of N+C peptide
complexes; whereas the N or C peptide alone failed to adsorb out all of
the antibodies. These results conﬁrm that elevated temperature
triggers RSV F protein 6HB formation on the surface of infected cells.
Discussion
In this study, we describe the generation of reagents and identi-
ﬁcation of a system that permits the study of 6HB formation directly in
native,membrane-anchored F protein expressed on the surface of RSV-
infected cells. Using conformation-speciﬁc antibodies to the RSV F 6HB
structure, we directly demonstrate that elevated temperature is an
efﬁcient trigger of F protein conformational change. The ﬂow
cytometry-based assay described in this report is an attractive starting
Fig. 8. Cell-surface IP demonstrates temperature-induced triggering of six-helix bundle formation in cell-surface-expressed F protein. (A) 6HB formation increases as a function of
increasing temperature. A qualitative increase in F1 subunit immunoprecipitation was observed in the samples triggered at 55 or 50 °C for 15 min (lanes 6 and 7) as compared to
those triggered at 37 °C (lane 5). The amount of F1 subunit immunoprecipitated following 45 °C triggering appeared to be somewhat lower than that observed at 50–55 °C; however,
it still appeared to be higher than that observed at 37 or 40 °C (compare lane 8 with lanes 5 and 9, respectively). Lane 1 is a control showing F expression in RSV-infected cells
immunoprecipitated with an anti-F monoclonal antibody (858-1). The pre-immunization serum (PI) did not immunoprecipitate any relevant proteins either in uninfected or RSV-
infected cells (lanes 2 and 3). (B) Speciﬁcity of the α-NC antiserum binding at elevated temperature for 6HB epitope. Increased amount of 6HB formed during elevated temperature
can be adsorbed out with corresponding 6HB peptides. The α-NC antiserum was preadsorbed with 5 μg each of peptides NC, N, C, or N+C, respectively or PBS (−) overnight at 4 °C
and used in triggering experiments at 55 °C for 15 min as described above. The NC and N+C peptides appeared to almost completely adsorb out the reactivity of α-NC antiserum at
55 °C (compare lanes 3 and 6 with lane 2). The adsorption of α-NC antiserum with N peptide alone (lane 4) or C peptide alone (lane 5) did not appear to signiﬁcantly impair their
ability to immunoprecipitate F1 subunit.
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fusion inhibitors. We have previously used a similar approach success-
fully to study HIV-1 gp41 6HB formation following triggeringwith CD4
and to identify small molecule inhibitors of HIV-1 fusion (Salzwedel et
al., unpublished results, Furuta et al., 1998; de Rosny et al., 2001).
The physiologic triggers that activate conformational changes in
RSV F are not known. The activation of most paramyxovirus F proteins
at neutral pH is triggered by a three-step process including (1) binding
of a viral receptor-binding protein such as HN or H to its cellular
receptor; (2) interaction of HNwith F, and (3) conformational changes
in F that mediate membrane fusion (Russell et al., 2001; Takimoto
et al., 2002). Coexpression of homotypic receptor binding protein is
required for efﬁcient fusion activity of F (for a review, see Lamb &
Kolakofsky, 2001). In the case of RSV, G protein mediates attachment;
however, G is not absolutely essential for fusion (Karron et al., 1997;
Kahn et al., 1999; Teecharpornkul et al., 2001). The RSV F protein alone
canmediate infection and syncytia formation entirely in the absence of
G, suggesting that the RSV-F1+F2 complex, like HIV gp120-gp41,
carries all the domains necessary tomediatemembrane fusion (Collins
et al., 2001; Karron et al., 1997; Bukreyev et al., 1997; Kahn et al., 1999;
Teecharpornkul et al., 2001). In the case of HIV, the fusion protein,
gp41, is triggered by binding of its associated subunit (gp120) to CD4
receptor on the target cell surface (Hernandez et al., 1996). Since, like
HIV, RSV fusion takes place at the cell surface and is pH-independent
(Collins et al., 2001), it is likely that F protein also interacts with a cell-
surface receptor, although such a receptor has not yet been identiﬁed.
The conformational change in HIV-1 gp41 leading to 6HB for-
mation can be triggered in vitro in HIV-1-infected cells by addition of
soluble CD4 and detected with 6HB-speciﬁc antibodies generated by
peptide immunization (Furuta et al., 1998; de Rosny et al., 2001;
Kilgore et al., 2003, Salzwedel et al., unpublished results). In the
absence of a known receptor that can trigger RSV F, we looked at other
viral systems with similar mechanism of fusion and tested several
possible 6HB triggers in a ﬂow cytometry assay. After a thoroughliterature search, we selected the following approaches with some
rationale for testing in the ﬂow cytometry assay: Rho A (Pastey et al.,
2000); ICAM-1 (Behera et al., 2001); human/bovine lactoferrin (Sano
et al., 2003); Iduronic acid containing glycosaminoglycans (GAG)
including dextran sulfate, chondroitin sulfate, heparin sulfate and
heparin (Hallak et al., 2000; Feldman et al., 2000); trypsin treatment
to enhance F2 internal cleavage (Gonzalez-Reyes et al., 2001; Zimmer
et al., 2001); pH range 3.2 –11.0 (Hernandez et al., 1996; Mothes
et al., 2000; Sturman et al., 1990; Zelus et al., 2003; Hsu et al., 1982;
Holmes and Choppin 1966; Plemper et al., 2003); destabilizing F2–F1
arrangement with dithiothreitol(dTT) and β-mercaptoethanol (β-
ME) (Plemper et al., 2003; Barbouche et al., 2003; Gallina et al., 2002)
and mild denaturant, 0.05% sodium dodecyl sulfate (SDS). None of
these approaches resulted in a clear, consistent triggering effect (data
not shown).
We could not test hydrostatic pressure for its reported effect to
induce fusion active state due to the need for specialized equipment
(Gaspar et al., 2002). Similarly we could not test urea or guanidine HCl
in our system due to their deleterious effect on cells (Ruigrok et al.,
1986; Paterson et al., 2000; Wharton et al., 2000).
A few early studies discovered that the low pH-triggering effect for
inﬂuenza hemagglutinin (HA) could be substituted by elevated
temperature in the range of 58–62 °C (Wharton et al., 1986; Haywood
and Boyer, 1986; Ruigrok et al., 1987). The heat-triggered conforma-
tional change in HA coincided with the formation of a fusogenic 6HB
conformation that is biochemically indistinguishable from the lowpH-
triggered conformation (Carr et al., 1997). These studies suggested to
us that elevated temperature could potentially serve as a trigger for
RSV F protein. Using theαNC antibody as a probe, we observed in ﬂow
cytometry and cell-surface IP experiments that exposure of RSV-
infected cells to a temperature of 45–55 °C for 5–15minwas sufﬁcient
to cause a 3- to 5-fold increase in the formation of 6HB conformation of
F (Figs. 7B andC).We concluded that elevated temperature could serve
as an efﬁcient in vitro trigger of 6HB formation in RSV-F.
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possibility that the α-NC antibodies may recognize a conformation of
the HR2 domain that is not represented by the free C peptide. Such an
epitope could potentially be unmasked by partial denaturation during
incubation at elevated temperature andmay not faithfully represent a
conformation of the F protein that is related to authentic conforma-
tional changes. Alternatively, it is possible that the antibodies may
detect an intermediate conformation of the F protein rather than the
post-fusion 6HB structure. However, we consider these scenarios to
be unlikely, given the results obtained.
Our ﬁnding is consistent with similar observations in the other
paramyxoviruses (Wharton et al., 2000; Paterson et al., 2000; Seth
et al., 2003; Russell et al., 2001). Notably, Wharton et al. (2000)
observed that following exposure to 55 °C, Sendai virus fusion protein
assumes the 6HB conformation. Pre-incubation of Sendai virus at that
temperature (55 °C) blocked fusion by inactivating the F protein,
presumably by pre-triggering 6HB formation in the absence of the
target membrane (Wharton et al., 2000). Patterson and co-workers
workingwith SV5-Fmutants that required coexpression of homotypic
HN protein to promote membrane fusion demonstrated that the
requirement of HN for F triggering can be replaced by elevated
temperature (Paterson et al., 2000). More recently, for a newly
identiﬁed paramyxovirus—SER virus (a rubula virus)—elevated
temperature in the range of 55–65 °C could enhance hemifusion,
cytoplasmic content mixing, and syncytium formation in dye-transfer
experiments between SER F-expressing cells and dye-labeled guinea
pig RBC (Seth et al., 2003).
More recently, Connolly et al. (2006) engineered a soluble form of
the parainﬂuenza virus 5 fusion protein in its pre-fusion state, wherein
the functionof the transmembraneanchor domain (TM)waspreserved
by replacing it with a trimerization domain (PIV5 F-GCNt). The authors
demonstrated that this form of the protein could be triggered to
undergo conformational change to its more stable post-fusion state by
heating to 50 °C (range: 45 –60 °C). Upon triggering at 50 °C, PIV5-F
GCNt associated with liposome membranes, formed rosettes, and lost
or gained reactivity to conformation-speciﬁc antibodies that were
predicted to recognize pre- or post-fusion conformational states,
respectively. A change in the shape of the soluble protein from a
prefusion “ball-and-stem” to a more elongated post-fusion “golf-tee”
shapewas also observedbyelectronmicroscopy (Connolly et al., 2006).
Thus, our ﬁndings that elevated temperature serves as a surrogate
trigger of RSV F conformational changes is consistent with previous
studies of F protein conformational change in other paramyxovirus
systems (Lamb and Jardetzky, 2007).
Study of the process of conformation change in fusion proteins
from a diverse group of enveloped viruses including SV5, inﬂuenza
HA, and HIV have led to the development of a ‘spring-loaded trap’
model (Carr et al., 1997; Russell et al., 2001). In this model, it is
suggested that the non-fusogenic neutral pH conformation of viral
fusion glycoproteins (vFGps), including the native F1–F2 complex in
paramyxoviruses such as RSV, exists in a kinetically trapped high-
energy state and that energy is released as a result of conformation
change in the protein. In agreement with the spring-trap model,
at neutral pH, heat, urea, or pressure can ‘loosen’ the native non-
fusogenic form, causing it to transition spontaneously into a fusogenic
form, suggesting that the native state of vFGps is ‘metastable’ (Carr
et al., 1997; Paterson et al., 2000; Wharton et al., 2000; Gaspar et al.,
2002; Epand and Epand, 2002). These studies also propose that
physiological triggers such as pH change or receptor binding fulﬁll a
common energy requirement for performing the work of membrane
fusion that could be satisﬁed directly by an increase in temperature or
other destabilizing force such as urea or pressure (Patterson et al.,
2000; Wharton et al., 1986, 2000; Carr et al., 1997; Haywood and
Boyer, 1986; Ruigrok et al., 1987; Epand and Epand, 2002; Seth et al.,
2003). The energy released during the 6HB formation is used to
perform the work of membrane fusion (Melikyan et al., 2000). Ourdemonstration here that heat can trigger the formation of the 6HB
structure in the RSV fusion protein is consistent with the native state
of RSV F protein existing in a metastable state. Our ﬁndings, therefore,
extend the metastability hypothesis to RSV, a member of the
pneumovirus genus in the family Paramyxoviridae.
The assay system described in this report has potential applica-
tions in the testing of future RSV receptor candidates by measuring
their triggering effect on F protein conformational change. Similarly,
this approach could be used to further study the requirements for 6HB
formation in native RSV F. For example: Do RSV G or SH proteins have
any inﬂuence on this effect? Does F0 undergo the same conforma-
tional change as cleaved F1? The thermal triggering approach could
also be adapted to study the conformational changes of fusion
proteins from other viruses for which receptors have yet to be
identiﬁed. The triggering event and the conformational changes in the
RSV F protein leading to 6HB formation are attractive antiviral targets,
since disruption of these key steps can prevent F protein mediated
membrane fusion. For treating HIV infection, a C peptide inhibitor
(enfuvirtide; T-20) has been approved that targets the HIV gp41
fusion protein during an intermediate stage of conformational change
to form a dead-end peptide-gp41 hybrid six-helix bundle structure
(Wild et al., 1994; Kilgore et al., 2003; Matthews et al., 2004). Thus,
inhibition of viral fusion protein six-helix bundle formation is a
validated therapeutic approach for the treatment of viral disease. The
RSV 6HB antibody probe and temperature triggering technique that
we describe could be applied towards the development of high-
throughput drug screening assays to identify small molecule drugs
that speciﬁcally block the conformation changes in the fusion protein.
Proof-of-concept for this idea has been provided by the identiﬁcation
of an inﬂuenza virus fusion inhibitor capable of blocking temperature-
induced 6HB formation in inﬂuenza virus HA (Yoshimoto et al., 1999).
Materials and methods
Cells, viruses, and antibodies
Vero cells and the A2 strain of human RSV were obtained from the
ATCC. Cells were cultured in Dulbecco'smodiﬁed Eagle'smediumwith
10% fetal bovine serum containing antibiotics. Virus was propagated
and titrated in Vero cells. The following antibodies were used: anti-
RSV polyclonal antibodies (B65860G, Biodesign), anti-F protein mAb
(RSV3216, Serotec), anti-F protein mAb (858-1, Chemicon), anti-G
protein mAb (858-2, Chemicon), anti-RhoA mAb (26C4, sc-418, Santa
Cruz Biotechnology), anti-Golgi mAb (G-2404, Sigma), donkey anti-
goat IgG-HRP (AP180P, Chemicon).
Construction of synthetic genes encoding RSV F protein heptad
repeat peptides
Synthetic genes encoding the heptad repeat regions, HR1 (N) and
HR2 (C), of RSV F protein (A2 strain; accession no. VGNZA2) were
designed based on the work of Zhao et al. (2000) and codon
optimized for optimal expression in E. coli (Fig. 1). A cDNA construct
(HR1/HR2) encoding both heptad repeat regions, HR1 (amino acid
residues 153–209 of RSV F) and HR2 (amino acid residues 476–520 of
RSV F), linked via a glycine-rich linker was generated (Figs. 1B and C).
Brieﬂy, a series of overlapping complementary oligonucleotides
spanning the entire length of either the N or C coding sequence was
designed. The codons within the oligo sequences were biased for
optimal expression in E. coli (Fig. 1B). The oligos were annealed and
extended in the appropriate order in successive PCR reactions to form
two complete double-stranded DNAs encoding either N peptide (HR1)
or C peptide (HR2). The resulting HR1 or HR2 PCR products were then
re-ampliﬁed in aﬁnal PCR reactionusing an upstreamprimer encoding
a BamHI– factor-Xa cleavage sequence (residues IEGR) at the 5′ end
and a reverse primer encoding the restriction site HindIII at the 3′ end.
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HindIII sites of the pET32a bacterial expression vector (Novagen) to
generate the cDNAs HR1 or HR2, respectively. The linked HR1/HR2
cDNA(Fig. 1B)was constructedbyﬁrst amplifying the individual cDNA
fragments, HR1 and HR2, in separate PCR reactions using comple-
mentary, overlapping primers that encoded each half of the inter-
vening linker sequence, as well as a unique KpnI site at their 5′ ends.
The resulting PCR fragments encoding HR1 or HR2 were then ligated
together at their KpnI site to yield a fragment encoding both HR1 and
HR2, joined via a glycine-rich linker (NC; Fig. 1C). The ligatedHR1/HR2
was ampliﬁed oncemore in a PCR reaction using a primer encoding the
5′ end of HR1 and a primer encoding the 3′ end of HR2. The ﬁnal
product was cloned via BamHI–HindIII into the pET32a vector to yield
the HR1/HR2 cDNA that encoded the single-chain NC peptide (Fig. 1B
and C). The constructs HR1, HR2, and HR1/HR2 were sequenced in
their entirety. The hexahistidine tag encoded in the pET32a vector
allowed for histidine afﬁnity puriﬁcation of the fusion peptide.
Peptide expression and puriﬁcation
The recombinant RSV peptides were expressed as histidine-tagged
fusion proteins in E. coli (Figs. 1B, C, and 2A). The plasmids HR1, HR2,
or HR1/HR2 were transformed into E. coli strain pLysS (Novagen) for
protein expression. Individual colonies of transformed bacteria were
inoculated into Luria-Bertani (LB) broth and grown to an optical
density of 0.6 at 600 nm. Protein expression was induced with 1 mM
isopropyl-β-D-thiogalactopyranoside for 3 h. The cells were harvested
by pelleting in a centrifuge. The cell pellet was lysed with Benzonase
reagent (Novagen), and lysate was clariﬁed by centrifugation. The
histidine-tagged fusion proteins in the lysates were captured on Ni+2
afﬁnity columns. The eluted histidine-tagged fusion proteins were
dialyzed against factor-Xa cleavage buffer (50 mM Tris–HCl [pH 8.0]–
100 mM NaCl-2 mM CaCl2) in order to set up factor-Xa digestion. The
fusion proteins were digested with factor-Xa (1:500 wt/wt ratio of
protease:tagged protein) for 24 h at room temperature to remove the
leader peptide and histidine tag residues. The leader peptide–
histidine tag was removed from the cleavage mixture by passing the
mixture over a Ni+2 afﬁnity column; the ﬂowthrough contained the
RSV peptides (N, C, or NC) (Fig. 2A). The N and NC peptides were
further desalted by passing through PD-10 Sephadex columns. The
peptides were lyophilized and resuspended in ultra pure water. The
RSV peptides (N, C, or NC) were each adjusted to 0.5 mg/ml ﬁnal
concentration.
Conﬁrmation of molecular weight and reactivity to RSV polyclonal serum
by immunoblot
Puriﬁed N, C, or NC peptides, along with their histidine-tagged
forms, were separated by sodiumdodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) using 12% polyacrylamide Bis-Tris Novex
gels (Invitrogen) alongside Multimark molecular weight marker and a
commercially synthesized peptide of known molecular weight
(∼4.5 kDa). The proteins were detected by Coomassie blue staining.
In order to ascertain if the synthetic peptides could be recognized
by anti-RSV (αRSV) antibodies, the puriﬁed N, C, or NC peptides were
separated by SDS-PAGE as above, transferred to a nitrocellulose
membrane, and probed with goat αRSV polyclonal serum. Antibody
binding was detected using a horseradish peroxidase-conjugated
anti-goat secondary antibody and the ECL chemiluminescent detec-
tion system (Amersham Pharmacia Biotech).
Determination of antiviral activity of peptides
The N, C, and NC peptides or a 1:1 equimolar mixture of N and C
peptides (N+C) was tested in a dose–response assay for their ability
to inhibit RSV-mediated cell fusion and infection in vitro using amodiﬁcation of an RSV microneutralization assay (Johnson, 1997).
Brieﬂy, 100 TCID50 of RSV was mixed with various concentrations of
each RSV peptide. After a 1-h pre-incubation at room temperature, the
peptide/virus mixture was added to a Vero cell monolayer in a 96-
well plate (2×104 cells/well). The plates were incubated at 37 °C for 5
days and then scored visually for inhibition of virus-mediated cell
killing.
Circular dichroism studies
CD measurements were obtained with an Aviv Associates model
202 spectropolarimeter calibrated with a standard solution of 10-
camphorsulfonic acid as per Wild et al. (1992). Samples contained
10–50 μM total concentration of peptide (either NC or the N+C
peptide mixture) in 0.1 M NaCl/10 mM potassium phosphate,
adjusted to pH 7.0. Spectra were collected at 1 °C with 1.5 mM
bandwidth, a 0. 5-nm step size, and a 2.0-s time constant in either 1-
or 10-mm path-length cells. Blank-corrected data were smoothed
with a third-order polynomial function. A thermoelectric cell holder
accurate to within 1 °C regulated sample temperature.
Immunization protocol
To generate antibodies against the RSV F protein 6HB structure,
two groups of 3 guinea pigs were immunized with either the single-
chain peptide, NC, or an equimolar (1:1) mixture of the N and C
peptides, N+C. All of the animals were primed subcutaneously with
200 μg of total peptide in complete Freund's adjuvant and boosted
three times with 100 μg peptide in incomplete Freund's adjuvant. The
pre-immunization (PI) sera and ﬁnal bleeds post-immunization were
stored at –20 °C.
Peptide ELISA
An indirect ELISA was established to determine the reactivity of
anti-NC (αNC) or anti-N+C (αN+C) antiserum to RSV peptides (N,
C, NC, and the N+C mixture). Ninety-six-well Immulon-2 plates
(VWR cat. # 62402-972) were coated with 100 ng/well of each
peptide antigen. After blocking with 1% BSA, serum samples were
added in duplicate and allowed to incubate for 2 h at 37 °C. After
incubation, the plates were washed in PBS–0.05% Tween-20 and a
phosphatase-labeled anti-guinea pig secondary antibody was added
at a 1:5000 dilution. After a 1-h incubation at room temperature with
the secondary antibody, substrate (fast p-nitrophenyl phosphate,
Sigma) was added, and absorbance was detected at 405 nm in a plate
reader.
RSV immunoblot
Immunoblot strips prepared from RSV-infected cell lysate were
probed with αNC or αN+C antiserum. Brieﬂy, a lysate was prepared
from RSV-infected Vero cells. RSV proteins in the lysate were
separated by SDS-PAGE (12%). The proteins were then transferred
to a nitrocellulose membrane and strips were prepared for probing
individually with different antibodies to RSV proteins. The RSV lysate
strips were probedwithαN+C orαNC serum at a dilution of 1:500 in
5% milk-PBS. The strip blots were probed with peroxidase-conjugated
secondary antibody, followed by detection using the ECL chemilumi-
nescent detection system.
Lysate immunoprecipitation
The αNC and αN+C antisera were tested for their ability to
immunoprecipitate RSV proteins from the lysates of RSV-infected
cells. RSV-infected Vero cells were lysed in 0.2 ml lysis buffer (1%
Nonidet P-40-150 mM NaCl-100 mM Tris [pH 8.0]) and clariﬁed by
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αN+C antiserumwas added to clariﬁed lysate and incubated for 1 h at
4 °C. Protein G agarose beads (Invitrogen) were then added and
incubated for 1 h at 4 °C. The antigen–antibody–bead complexes were
washedﬁve times inwashbuffer (0.1% SDS, 300mMNaCl–0.5% IGEPAL,
50 mM Tris [pH 7.5]) and resuspended in protein-loading buffer
(Invitrogen). The immunoprecipitated proteins were separated by
SDS-PAGE (10%). The proteinswere then transferred to a nitrocellulose
membrane, the membrane was blocked in blocking buffer (5% milk-
PBS) and probed with a α-RSV polyclonal antibody (Biodesign
International cat. # B65860G) at a 1:500 dilution in blocking buffer.
The blots were washed and probed with a horseradish peroxidase-
conjugated donkey anti-goat secondary antibody (Chemicon Inter-
national cat. # AP180P) at a dilution of 1:10,000 in blocking buffer. The
blots were washed again and the proteins were detected by chemi-
luminescence using the ECL chemiluminescent detection system.
Cell-surface immunoprecipitation
Cell-surface immunoprecipitation (IP) was used to selectively
immunoprecipitate the fusion protein expressed on the cell surface of
RSV-infected Vero cells. Vero cells were infectedwith RSV at 0.03–0.05
MOI. 48 h post-infection the RSV-infected Vero monolayer was
washed three times with PBS and resuspended into a single-cell
suspension using enzyme-free cell dissociation buffer (Invitrogen).
The cells were pelleted and resuspended in stain/wash buffer (SWB:
PBS containing 1% BSA–0.1% NaN3) at a concentration of 2×107 cells/
ml. 100 μl of cell suspension (2×106 cells) was used for each cell-
surface IP. 2 μl of primary antibody,αNCorα-Fmonoclonal (Chemicon
International # MAB858-1) was used in each IP. The antibody–cell
mixture was incubated for 1 h at 4 °C. Following this, the cells were
washed twice with PBS and lysed in 0.2 ml lysis buffer. The clariﬁed
lysate was then processed and analyzed as described in lysate-IP
experiment. The immunoprecipitated proteins were separated using
SDS-PAGE (10%) and immunoblotting was performed as for the lysate
IP described above.
In temperature triggering cell-surface IP experiments, amastermix
was prepared wherein αNC antibody was added at the concentration
of 2.0 μl /100 μl of RSV-infected Vero cells (2×106 cells) resuspended
in SWB. After thorough mixing, 100 μl aliquots were distributed into
0.5 ml PCR tubes for heat treatment in a thermocycler. The cells were
exposed to elevated temperature in the range of 4 –55 °C (or the
indicated temperature) for 5–15 min (or the indicated time period).
Following temperature treatment, all subsequent steps of the cell-
surface IP and immunoblotting were performed as described above.
Flow cytometry
Antibody staining and ﬂow cytometry analysis was used to
determine the level of F protein 6HB present on the surface of RSV-
infected cells. RSV-infected Vero cells were resuspended in stain/
wash buffer at a concentration of 2×107 cells/ml. Fifty microliters
(1×106 cells) of the cell suspension was used for ﬂow cytometry. A
1:50 dilution (2.0 μl) of αNC or control monoclonal antibodies αF or
αG were used as primary antibodies for each ﬂow cytometry sample.
The cells were incubated with antiserum for 1 h at 4 °C and then
washed twice in stain/wash buffer. A secondary antibody, FITC-
labeled α-guinea pig antibody at a ﬁnal concentration of 1 μg/ml in
stain/wash buffer was added to each sample and incubated for 45min
at 4 °C. The cells were washed twice and then resuspended in stain/
wash buffer and analyzed using a Becton Dickinson FACSCalibur ﬂow
cytometer and CellQuest software.
Flow cytometry in the above format was used as a screening assay
to search for potential trigger of RSV 6HB formation. We tested a wide
variety of ligands and conditions such as recombinant RhoA protein
(Cytoskeleton Inc. # RHO1-B) or recombinant ICAM-1(R&D SystemsInc. # ADP4); Glycosaminoglycans such as heparin, dextran sulphate,
chondroitin sulphate B (Sigma); Lactoferrin bovine or human
(Sigma), pH in the range of 11–3.2, trypsin; disulphide bond reducing
agents like dTT or β-Mercaptoethanol; denaturing agent such as SDS
(Pastey et al., 2000; Behera et al., 2001; Sano et al., 2003; Hallak et al.,
2000; Feldman et al., 2000; Gonzales-Reyes et al., 2001; Zimmer et al.,
2001; Plemper et al., 2003; Barbouche et al., 2003; Gallina et al., 2002).
We exposed RSV-infected Vero cells to elevated temperature (above
37 °C up to 65 °C) for varying time period in course of identifying
temperature as a trigger of 6HB formation of RSV F protein.
The integrity of the cells following triggering at 55 °C was further
conﬁrmed using control antibodies to intracellular proteins Rho A or
Golgi complex. In order to compare the level of staining obtained at
55 °C with that obtained following a true-cell membrane permeabi-
lization effect, we used a cell permeabilization buffer (Perm2 FACS-
permeabilizing solution 2, Becton Dickinson) to permeabilize the cells
prior to ﬂow cytometry staining. RSV-infected Vero cells per milliliter
(2×107) or uninfected Vero cells were treated with 1× Perm 2 buffer
as permanufacturer's recommendation. Brieﬂy, the cellswere exposed
to 1×Perm2 solutionprepared inwater for 0.5 h, followedby 2washes
in stain/wash buffer and resuspended back into original cell
concentration (i.e., 2×107 cells/ml). A 50 μl (= 1×106 cells) aliquot
of cells was used in each ﬂow cytometry experiment as above. The
staining to cellular protein ‘RhoA’ or a cell-organelle ‘Golgi complex’
was determined with monoclonal antibodies α-RhoA (Santa Cruz
Biotechnology Inc. # SC418) or α-Golgi, (Sigma #2404), respectively.Acknowledgments
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